Search Results for "Pharmac Cost Of Sativex In New Zealand"

19:11 EDT 22nd October 2014 | BioPortfolio

Matching Channels

Marginal cost

TASH Biotechnology

Shanghai TASH Biotechnology Co.,Ltd. specializes in peptide development on the basis of high technology. TASH Biotechnology are focusing on custom peptide synthesis, and the research, development...


BAC’s CaptureSelect products are affinity ligands and affinity resins created by a proprietary technology based on Camelid-derived single domain antibody fragments for the purification of biop...


CombiCult® is an award winning, combinatorial screening technology that allows scientists to discover new and improved stem cell differentiation protocols. How Combicult® works A short o...

Latin America

Latin America encompasses the Caribbean, South America and Central America. These countries are important players in the biotechnology industry, not only as consumers, but as contributors. The env...

Matching News

Bayer’s Jadelle to be listed in New Zealand

New Zealand’s Pharmaceutical Management Agency PHARMAC has announced the approval of an agreement with Bayer New Zealand, the local subsidiary of German pharma major Bayer (BAYN: DE) for the listing...

Major step forward for multiple sclerosis treatment in New Zealand

Funding for newer and more effective multiple sclerosis (MS) treatments has been approved by PHARMAC, New Zealand’s Pharmaceutical Management Agency.

New Zealand to fund Vidaza and Revlimid

New Zealand’s Pharmaceutical Management Agency PHARMAC says it has approved a proposal for funding two oncology products - azacitidine (Vidaza), lenalidomide (Revlimid) and thalidomide (Thalomid), ...

New treatment funded for severe gout in New Zealand

Patients with severe gout will soon have a new treatment option as New Zealand’s Pharmaceutical Management Agency PHARMAC will be funding febuxostat (trade name Adenuric) from June 1, 2014.

New Zealand approval of Novartis multiproduct proposal

New Zealand’s Pharmaceutical Management Agency PHARMAC has announced the approval of an agreement with the local subsidiary of Swiss pharma giant Novartis involving the listing of nine new products ...

Changes to the funding access criteria for some vaccines in New Zealand

New Zealand’s Pharmaceutical Management Agency, PHARMAC, this morning announced changes to the funding access criteria for a number of vaccines.

NZ’s PHARMAC awards sole supply to Eprex to Janssen-Cilag

New Zealand’s Pharmaceutical Management Agency PHARMAC has awarded sole subsidised supply status in the community, and hospital supply status in District Health Boards (DHB) hospitals, to US health ...

Multiple sclerosis treatments funding proposal in New Zealand

New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on a funding proposal involving five treatments for multiple sclerosis (MS), including two new treatments that are not curr...

Matching PubMed Articles

Rehabilitation in the New Zealand logging industry.

Work within the New Zealand logging industry is recognised as being dangerous and physically demanding, with relatively high accident and injury frequency rates. As a consequence, the financial cost o...

Opioid substitution treatment in New Zealand: a 40 year perspective.

We provide an overview of the history and philosophy of the treatment for opioid dependence, which has been dominated by methadone substitution treatment for the past 40 years in New Zealand. Although...

Cost of traumatic brain injury in New Zealand: Evidence from a population-based study.

We aimed to estimate from a societal perspective the 1-year and lifetime direct and indirect costs of traumatic brain injury (TBI) for New Zealand (NZ) in 2010 projected to 2020.

Translation of research into clinical practice: a case study of calcium supplement prescribing in New Zealand.

Researchers are commonly requested to describe potential benefits of their research for New Zealand in funding applications, but such benefits can be difficult to precisely determine. Recently, we rep...

Current trends and projections in the utilisation rates of hip and knee replacement in New Zealand from 2001 to 2026.

This study aimed to estimate the demand for total hip (THR) and knee replacements (TKR) by 2026 within New Zealand (NZ) and show how demographic factors are likely to influence this projection.

Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement